COLORADO SPRINGS, Colo., Aug. 8 /PRNewswire-FirstCall/ -- Spectranetics Corporation (Nasdaq: SPNC) announced today the Company's CLiRpath(R) Excimer Laser Catheter was featured in the August 2005 edition of Podiatry Today. The article highlighted the trade publication's annual roundup of 10 current and emerging innovations that may prove beneficial to podiatrists and their patients. The feature article included detail on the use and benefits of the Spectranetics CLiRpath excimer laser catheters for treating artery blockages in the leg, and providing greater flexibility for the interventionalist and podiatrist to avoid amputation due to peripheral vascular disease and critical limb ischemia (CLI).

"Podiatrists are an extremely important referral source to CliRpath users, and our public relations initiatives and podiatry outreach programs continue to build an awareness of the advantages of early diagnosis and minimally invasive treatment of CLI with our CLiRpath excimer laser catheters," said John G. Schulte, president and chief executive officer of Spectranetics. "We are delighted to be included among the Top 10 innovations by Podiatry Today. This is the latest of several recent news articles highlighting the advantages of treating peripheral vascular disease with our CLiRpath excimer laser catheters and the life-changing outcomes to patients."

Quoting David G. Armstrong, DPM, Ph.D., a member of the National Board of Directors of the American Diabetes Association, the article states, "The laser blasts through obstructions to restore blood flow and also provides an opportunity to traverse the site with a guidewire that can balloon the stenosis."

More information on this and other recent articles and news segments featuring Spectranetics' CLiRpath excimer laser catheters can be found on the Company's website at www.spectranetics.com.

CLiRpath Excimer Laser Catheters are indicated for use in the endovascular treatment of symptomatic infrainguinal lower extremity vascular disease where total obstructions cannot be crossed with standard guide wires.

About Podiatry Today

Podiatry Today is a source for informative, how-to clinical articles and practice management features for podiatrists. The magazine also offers the latest news affecting the profession and an array of regular columns, ranging from "Diabetes Watch" and "Surgical Pearls" to "Managed Care Insider."

About Spectranetics

Spectranetics is a medical device company that develops, manufactures and markets single-use medical devices used in minimally invasive surgical procedures within the cardiovascular system in conjunction with its proprietary excimer laser system. Its CVX-300(R) excimer laser is the only system approved by the FDA for multiple cardiovascular procedures, including coronary atherectomy, and the removal of problematic pacemaker and defibrillator leads. Nearly all of the company's FDA-approved and investigational applications have received Communautes Europeennes (CE) mark registration for marketing within Europe. In April 2004 Spectranetics obtained 510(k) clearance from the FDA for the laser-based treatment of patients suffering from total occlusions (blockages) in their leg arteries that are not crossable with a guide wire.

Safe Harbor Statement

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties may include increasing price and product competition, increased pressure on expense levels resulting from expanded marketing and clinical activities, uncertain success of the Company's strategic direction, dependence on new product development, intellectual property claims of third parties, availability of inventory from suppliers, the receipt of FDA approval to market new products or applications and the timeliness of any approvals, the potential size of market opportunities associated with new products, market acceptance of new products or applications, product defects, price volatility due to the initiation or cessation of coverage, or changes in ratings, by securities analysts. For a further list and description of such risks and uncertainties that could cause the actual results, performance or achievements of the Company to be materially different from any anticipated results, performance or achievements, please see the Company's previously filed SEC reports. Spectranetics disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether as a result of new information, future events or otherwise.

Spectranetics and CVX-300 are registered trademarks of The Spectranetics Corporation.

COMPANY CONTACT:
Spectranetics Corporation
Guy Childs, Chief Financial Officer
(719) 633-8333
www.spectranetics.com

INVESTOR & MEDIA CONTACTS:
Lippert/Heilshorn & Associates, Inc.
Bruce Voss or Zachary Bryant
(310) 691-7100
www.lhai.com

SOURCE Spectranetics Corporation